https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has corrected its US plant expansion plan to a single-batch 75,000L expansion (securing a total capacity of 141,000L) to respond to US pharmaceutical tariff policies and expand its CMO business. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN received an Audit Report with an ‘Unqualified’ opinion for both its consolidated and separate financial statements for FY2025 from Samil PwC. On a consolidated basis, revenue increased by 109.9% YoY to KRW 215.86B, while operating profit surged by 320.8% YoY to KRW 106.90B. 📊 [Key…
Read More “[Disclosure] ALTEOGEN (196170) – Submission of Audit Report / 2026-03-23” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary A serious industrial accident resulting in one fatality occurred during canopy drainage pipe work at Celltrion Plant 2, with official investigations and safety measure formulations underway. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Investigation Progress and Recurrence…
![[Disclosure] Samsung Biologics (207940) – Decision on Debt Guarantee for Others / 2026-03-20](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has resolved to provide a payment guarantee of approximately KRW 332.9B for the real estate lease agreement of a US entity acquired through its wholly owned US subsidiary. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Changes in…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has approved all agenda items at its 15th Annual General Meeting of Shareholders, including FY2025 financial statements with KRW 4.56T in revenue, the re-election of Inside Director John Chongbo Rim, and the re-election of Jung Yeon Kim as Outside Director while newly appointing her…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has decided to participate in a rights offering of its U.S. subsidiary (Samsung Biologics America) to acquire 350,000 new shares for approximately KRW 524.9B in cash. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Capital Payment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics’ U.S. subsidiary (Samsung Biologics America) has decided on a shareholder-directed rights offering of approximately KRW 524.9B to fund the acquisition of Human Genome Sciences in Rockville, U.S., and cover operating expenses. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Read More “[Disclosure] Samsung Biologics (207940) – Decision on Rights Offering / 2026-03-20” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will list an additional 28,055 common shares on March 20, 2026, following the conversion of preferred shares into common shares. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Outstanding Shares Update Following Additional Listing This…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has signed a contract manufacturing agreement (CMO) worth KRW 294.9B (8.29% of recent annual revenue) with a global pharmaceutical company. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Supply Commencement in Q1 2027 and Contract Execution Progress…
Read More “[Disclosure] Celltrion (068270) – Single Sales / Supply Contract / 2026-03-17” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will hold its 18th Annual General Meeting of Shareholders on March 31, 2026, at the Daejeon Convention Center. Agenda items include approval of financial statements (KRW 371 dividend per share), amendments to Articles of Incorporation, appointments of directors and Audit Committee members, and reduction of…